Abstracts related to the conduct of clinical trials, not the actual trials results, from ASCO can be found under the category Health Services Research.
Abstracts related to the conduct of clinical trials, not the actual trials results, from ASCO can be found under the category Health Services Research. Those are then broken down into four areas--
Following is a list of abstracts submitted to ASCO for either presentation at the event or for online only for topics related to clinical trials.
Access to Children’s Oncology Group Phase I clinical trials: Racial/ethnic dissimilarities in participation
http://abstracts.asco.org/144/AbstView_144_135104.html
Accrual of adolescents and young adults with cancer to eligible clinical trials: A report from the NCIC Clinical Trials Group (NCIC-CTG)
http://abstracts.asco.org/144/AbstView_144_129269.html
Discussions about clinical trials among patients with lung and colorectal cancer
http://abstracts.asco.org/144/AbstView_144_125834.html
Equity of access: Consent interpretation program at Princess Margaret Cancer Centre (PM) in Canada
http://abstracts.asco.org/144/AbstView_144_132592.html
Exclusion of patients with prior cancers from clinical trials: Is this justified?
http://abstracts.asco.org/144/AbstView_144_129732.html
FDA breakthrough therapy designation of oncology products: The first-year experience
http://abstracts.asco.org/144/AbstView_144_127621.html
Media reporting of practice-changing clinical trials in oncology: A North American perspective
http://abstracts.asco.org/144/AbstView_144_125552.html
Social media use amongst oncologists: Results of a national physician survey
http://abstracts.asco.org/144/AbstView_144_133064.html
Why is it so difficult to enroll patients in clinical trials?
http://abstracts.asco.org/144/AbstView_144_135223.html
Are new drugs more expensive than old ones? Trends in the benefit-adjusted launch prices of anticancer drugs, 1995-2013
http://abstracts.asco.org/144/AbstView_144_127523.html
Avoided cost in chemotherapy drugs by patient inclusion in clinical trials
http://abstracts.asco.org/144/AbstView_144_133187.html
Developing a predictive model for cancer clinical trial accrual
http://abstracts.asco.org/144/AbstView_144_129783.html
How much is the pharmaceutical industry's cost of capital for clinical research of novel drugs?
http://abstracts.asco.org/144/AbstView_144_131029.html
Hispanic accrual on randomized cancer clinical trials: A call to arms
http://abstracts.asco.org/144/AbstView_144_126803.html
Impact of prior cancer on eligibility for lung cancer clinical trials
http://abstracts.asco.org/144/AbstView_144_127107.html
A randomized, controlled study comparing NCI’s original and revised informed consent templates
http://abstracts.asco.org/144/AbstView_144_134327.html
A tool to help research programs exceed the minimum standards of conducting clinical research
http://abstracts.asco.org/144/AbstView_144_129898.html
A virtual consult service to optimize clinical trial participation in patients with metastatic breast cancer
http://abstracts.asco.org/144/AbstView_144_129240.html
An analysis of cancer-specific Twitter conversations among physicians in 2013
http://abstracts.asco.org/144/AbstView_144_132049.html
Are manufacturers targeting smaller patient populations and are they being rewarded for it?
http://abstracts.asco.org/144/AbstView_144_130102.html
Are preclinical research findings replicable: An empirical analysis based on EpoR studies in cancer
http://abstracts.asco.org/144/AbstView_144_135167.html
Audio visual recording of informed consent: Novel mandatory regulatory compliance for clinical trials in India
http://abstracts.asco.org/144/AbstView_144_134029.html
Clinical trial subjects compared to "real world" patients: Generalizability of renal cell carcinoma trials
http://abstracts.asco.org/144/AbstView_144_127782.html
Comparison of results between the first and updated reports of phase III clinical trials (RCTs)
http://abstracts.asco.org/144/AbstView_144_128899.html
Data quality in clinical trials
http://abstracts.asco.org/144/AbstView_144_128708.html
Development of a patient preference assessment tool for cancer patients considering phase I research
http://abstracts.asco.org/144/AbstView_144_127490.html
Development of a patient-reported outcome (PRO) measure for assessing non-small cell lung cancer (NSCLC) symptoms in clinical trials: Interim report from the PRO Consortium’s NSCLC Working Group (WG)
http://abstracts.asco.org/144/AbstView_144_130089.html
Drug-company–sponsored lectures and physicians' prescribing patterns
http://abstracts.asco.org/144/AbstView_144_125591.html
Impact of National Cancer Institute (NCI)-mandated scientific review on protocol development and content
http://abstracts.asco.org/144/AbstView_144_126777.html
Impact of the NCI Community Cancer Centers Program (NCCCP) on clinical trial (CT) activities in a community cancer center in rural Nebraska
http://abstracts.asco.org/144/AbstView_144_127658.html
Improving cancer clinical trial accrual in Ontario, Canada: The clinical trials infrastructure fund (CTIF) experience
http://abstracts.asco.org/144/AbstView_144_129298.html
Improving the patient (pt) experience through physician engagement
http://abstracts.asco.org/144/AbstView_144_131796.html
Mobile solution for clinical research documentation
http://abstracts.asco.org/144/AbstView_144_129293.html
NCI pilot intervention program to assist accrual for challenging late-phase clinical trials
http://abstracts.asco.org/144/AbstView_144_132024.html
Relationship between type of therapeutic intervention and funding source in randomized clinical trials (RCTs) in oncology
http://abstracts.asco.org/144/AbstView_144_132588.html
The clinical trial assessment of infrastructure matrix tool (CT AIM) to improve the quality of research conduct in the community
http://abstracts.asco.org/144/AbstView_144_126390.html
The road to assessing clinical trial-associated workload
http://abstracts.asco.org/144/AbstView_144_127100.html
Which formats for communicating patient-reported outcomes (PROs) work best?
http://abstracts.asco.org/144/AbstView_144_131765.html
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.